The FDA should not authorize the Pfizer jab for younger children until it conducts a proper trial
When Stephanie and Patrick de Garay enrolled their 12-year-old child Maddie and her two brothers in Pfizer’s Covid-19 clinical trial, they believed they were doing the right thing.
That decision has turned into a nightmare. Maddie, a previously healthy, energetic, full of life child, was within 24 hours of her second dose reduced to crippling, scream-inducing pain that landed her in the emergency room where she described feeling like someone was “ripping [her] heart out though [her] neck.”
Over the next several months the nightmare continued, during which Maddie was hospitalized several times and suffered numerous systemic injuries, requires a tube through her nose that carries her food and medicine, and a wheelchair for assistance.
Ms. de Garay documented every detail of Maddie’s injury and reported it to the principal investigator for the Pfizer trial at Cincinnati Children’s Hospital where the vaccine clinical trial was occurring and where Maddie was treated and admitted. They first tried to treat Maddie as “a mental patient,” telling the family it was psychological and in Maddie’s imagination. Then they claimed it was unrelated to the vaccine (copy of recording with hospital below), and when that argument failed, Pfizer listed this traumatic adverse event as “functional abdominal pain” when reporting to the FDA.